Your browser doesn't support javascript.
loading
Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
Kakara, Makoto; Larson, Kajal; Feng, Hwa-Ping; Shiomi, Mari; Yoshitsugu, Hiroyuki; Rizk, Matthew L.
Afiliação
  • Kakara M; Clinical Pharmacokinetics & Pharmacometrics Group, Clinical Pharmacology Development, Clinical Research Area, Japan Development, MSD K.K., Tokyo, Japan. Electronic address: makoto.kakara@merck.com.
  • Larson K; Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Feng HP; Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.
  • Shiomi M; Clinical Pharmacokinetics & Pharmacometrics Group, Clinical Pharmacology Development, Clinical Research Area, Japan Development, MSD K.K., Tokyo, Japan.
  • Yoshitsugu H; Clinical Pharmacokinetics & Pharmacometrics Group, Clinical Pharmacology Development, Clinical Research Area, Japan Development, MSD K.K., Tokyo, Japan.
  • Rizk ML; Department of Pharmacokinetics, Pharmacodynamics, and Drug Metabolism, Merck & Co., Inc., Kenilworth, NJ, USA.
J Infect Chemother ; 25(3): 182-191, 2019 Mar.
Article em En | MEDLINE | ID: mdl-30528208

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Urinárias / Cefalosporinas / Infecções Intra-Abdominais / Tazobactam / Antibacterianos Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Urinárias / Cefalosporinas / Infecções Intra-Abdominais / Tazobactam / Antibacterianos Idioma: En Ano de publicação: 2019 Tipo de documento: Article